CANTOS post-hoc trial: TET2-mutant carriers had a greater reduction in recurrent CV events with IL-1β inhibitor canakinumab. IL-6 signaling deficiency reduced CVD risk in CHIP. IL-6 blockade attenuates atherosclerosis in TET2-deficient mice. This evidence concerns the gene IL1B and atherosclerosis.